| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Cell Genesys Showing New Positive Study Data
Posted on 04/17/2007 13:51:19 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Cell Genesys, Inc. (CEGE-NASDAQ) is trading up more than 7% at $5.50 in earlybird trading on thin volume this morning on its new prostate cancer studies. Yesterday it closed down at $5.10, more than $2.00 off its its highs over the last 5-days. It recently raised cash as well to continue funding for Phase III's, but here is the data they are releasing:
....reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer. In addition, the antibody responses to this non patient- specific product were predominantly patient-specific and unique from patient to patient, indicating the potential advantage of a cell-based multi-antigen product such as GVAX to generate the broadest and most relevant immune response. Serological analysis of gene expression (SEREX) technology was also used to identify target antigens involved in response to the immunotherapy. More than 148 proteins to which antibody responses were induced were identified and many of these proteins had not been identified previously as prostate cancer-associated antigens. These findings were presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the annual meeting of the American Association for Clinical Research being held in Los Angeles, CA.
Here is the full link to the press release.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Cell Genesys Climbs On GVAX Results
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
______________________
24/7 Wall St.
Cell Genesys, Inc. (CEGE-NASDAQ) is trading up more than 7% at $5.50 in earlybird trading on thin volume this morning on its new prostate cancer studies. Yesterday it closed down at $5.10, more than $2.00 off its its highs over the last 5-days. It recently raised cash as well to continue funding for Phase III's, but here is the data they are releasing:
....reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer. In addition, the antibody responses to this non patient- specific product were predominantly patient-specific and unique from patient to patient, indicating the potential advantage of a cell-based multi-antigen product such as GVAX to generate the broadest and most relevant immune response. Serological analysis of gene expression (SEREX) technology was also used to identify target antigens involved in response to the immunotherapy. More than 148 proteins to which antibody responses were induced were identified and many of these proteins had not been identified previously as prostate cancer-associated antigens. These findings were presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the annual meeting of the American Association for Clinical Research being held in Los Angeles, CA.
Here is the full link to the press release.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Cell Genesys Climbs On GVAX Results
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Credit Bloggers
- The Average Joe Investor
- Wishing Wealth
- Financial Skeptic
- Edmonton Real Estate
- Don't Mess With Taxes
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]
Hedge funds have made billions this year shorting the banks, [read more]
<< My Home | TheMoneyBlogs Home